SG Americas Securities LLC Grows Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

SG Americas Securities LLC grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 410.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,944 shares of the biotechnology company’s stock after purchasing an additional 27,293 shares during the quarter. SG Americas Securities LLC owned approximately 0.06% of Ascendis Pharma A/S worth $4,673,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Westfield Capital Management Co. LP boosted its stake in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $60,000. Finally, ARS Investment Partners LLC raised its position in Ascendis Pharma A/S by 0.9% in the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock worth $36,549,000 after purchasing an additional 2,369 shares during the period.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $128.20 on Friday. The firm has a market capitalization of $7.78 billion, a P/E ratio of -15.87 and a beta of 0.65. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The company’s 50-day simple moving average is $133.28 and its 200 day simple moving average is $133.25.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. TD Cowen reduced their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Wedbush restated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.